



GJC  
#51  
(EOW)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:

Jonathan A. COATES et al.

Patent No.: 6,180,639 B1

Serial No.: 07/835,964

Issued: January 31, 2001

Filed: February 20, 1992

Title: 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

**PETITION FOR CERTIFICATE OF CORRECTION  
PURSUANT TO 37 C.F.R. § 1.322 OR § 1.323**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Certificate  
JUL 12 2006  
of Correction

Sir:

Patentees hereby request that the above-identified U.S. patent be corrected in accordance with the attached Certificate of Correction.

**I. C.F.R. § 1.322**

- ☒ The mistake was incurred through the fault of the Patent and Trademark Office and is clearly disclosed in the records of the Office. Therefore, no fee is due.

**II. C.F.R. § 1.323**

- ☐ The mistakes were made by patentees. Therefore, a check in the amount of \$100.00 in payment of the fee set forth in 37 C.F.R. § 1.20(a) is enclosed herewith.

Enclosed herewith is a Form PTO-1050 listing errors that have been found in the above-identified patent. The errors are of a clerical or typographical nature or of minor

2006  
JUL 12 2006

character and were made in good faith. The requested corrections do not constitute new matter or require reexamination.


III. Accordingly, patentees and their assignee respectfully request that the Patent and Trademark Office issue a Certificate of Correction pursuant to 37 C.F.R. § 1.322 or § 1.323, respectively.

IV. Additional Comments

Enclosed herewith is a copy of the Office Communication issued September 13, 2000 during the prosecution of the above-identified US patent. This Communication indicates that the Rule 312 Amendments filed March 7, 2000 and March 14, 2000 had been entered. In addition, the Communication included an Examiner's Amendment to claims 25 and 45.

However, when the patent issued it did not include the amendments presented in the Rule 312 Amendment filed March 14, 2000. Nor did it include both of the Examiner's Amendments presented in the Communication issued September 13, 2000. This Certificate of Correction merely inserts these amendments into the claims.

Respectfully submitted,


  
\_\_\_\_\_  
Brian P. Heaney, Reg. No. 32,542  
Attorney for Patentees

MILLEN, WHITE, ZELANO &  
BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No: IAFG-0014

Date July 10, 2006

JUL 13 2006



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Application No. <b>White, Zelano &amp; Branigan</b>	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
---	-------------	----------------------	---------------------

077835,964 02/20/92 COATES

J IAF 14

IAFG-14

EXAMINER

KRASS, F

ART UNIT

PAPER NUMBER

1614

DATE MAILED: 09/13/00

MILLEN, WHITE, ZELANO &  
BRANIGAN, P.C.  
ARLINGTON COURTHOUSE PLAZA I  
2200 CLARENDON BLVD., SUITE 1400  
ARLINGTON VA 22201

HM42/0913



Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

JUL 13 2006

**Response to Rule 312  
Communication**



Application No.  
**07/835,964**

Applicant(s)

**Coates et al.**

Examiner

**Frederick Krass**

Group Art Unit

**1614**



☐ The petition filed on \_\_\_\_\_ under 37 CFR 1.312(b) is granted. The paper has been forwarded to the examiner for consideration on the merits.

☒ The amendment filed on Mar 7, 2000 under 37 CFR 1.312 has been considered, and has been:

☒ entered.

☐ entered as directed to matters of form not affecting the scope of the invention (Order 3311).

☐ disapproved. See explanation below.

☐ entered in part. See explanation below.

  
**FREDERICK KRASS  
PRIMARY EXAMINER  
ART UNIT 1614**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

**Please find below a communication from the EXAMINER in charge of this application.**

Commissioner of Patents

The following corrections have been made by examiner's amendment in the claims, pursuant to a telephone request by Brian Heaney made 08-29-00:

Claim 25, sixth and seventh lines, "in said composition" has been deleted.

Claim 45, second line, "1" has been changed to --- 10 ---

Any inquiry concerning this communication or earlier communications regarding the substantive aspects of the communication (the action *per se*, questions regarding patentability, etc) from the examiner should be directed to Frederick Krass whose telephone number is (703) 308-4335. The examiner can normally be reached Monday-Friday from 7:30am to 3:00pm.

The examiner generally returns his phone calls in a very prompt manner. If attempts to reach the examiner by telephone are unsuccessful (allowing for a few days in case the examiner is on sick leave), the examiner's supervisor, Marianne Cintins, can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

JUL 13 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,180,639 B1

07/835964

DATED : January 31, 2001

INVENTOR(S) : Jonathan A. COATES et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 18, line 17, reads "human a phar-" should read -- human --  
Column 18, line 18, reads "maceuitcal composition comprising: a compound" should read -- a compound --  
Column 18, line 21, reads "thereof, another agent having antiviral activiy, and" should read -- thereof and --  
Column 18, line 22, reads "carrier, and" should read -- carrier --  
Column 18, line 25, reads "present in said composition is" should read -- present is --  
Column 18, line 27, reads "thereof." should read -- thereof, and another agent having antiviral activity. --  
Column 18, line 43, reads "wherein said compo-" should read -- wherein --  
Column 18, line 44, reads "sition contains an amount of the (+)-enantiomer of" should read -- the amount of the (+)-enantiomer is --  
Column 18, line 46, reads "wherein said compo-" should read -- wherein --  
Column 18, line 47, reads "sition contains an amount of the (+)-enantiomer of" should read -- the amount of the (+)-enantiomer is --  
Column 19, line 62, reads "wherein said com-" should read -- wherein --  
Column 19, line 63, reads "position contains an amount of the (+)-enantiomer of" should read -- the amount of the (+)-enantiomer is --  
Column 19, line 65, reads "wherein said com-" should read -- wherein --  
Column 19, line 66, reads "position contains and amount of the (+)-enantiomer of" should read -- the amount of the (+)-enantiomer is --  
Column 20, line 1, reads "wherein said com-" should read -- wherein --  
Column 20, line 2, reads "position contains an amount of the (+)-enantiomer of" should read -- the amount of the (+)-enantiomer is --  
Column 20, line 4, reads "wherein said com-" should read -- wherein --  
Column 20, line 5, reads "position contains an amount of the (+)-enantiomer of" should read -- the amount of the (+)-enantiomer is --  
Column 20, line 43, reads "human a phar-" should read --human --  
Column 20, line 44, reads "maceuitcal composition comprising: a compound" should read -- a compound --  
Column 20, line 47, reads "thereof, and another agent having antiviral activiy, " should read -- thereof, --  
Column 20, line 50, reads "present in said composition is" should read -- is --  
Column 20, line 52, reads "thereof." should read -- thereof, and another agent having antiviral activity. --  
Column 20, line 53, reads "said comp" should read -- said --  
Column 20, line 54, reads "position contains" should read -- compound is --

MAILING ADDRESS OF SENDER: Millen, White, Zelano & Branigan  
2200 Clarendon Blvd, Suite 1400  
Arlington, VA 22201

PATENT NO. 6,180,639B1

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2023

JUL 13 2006